9
Views
4
CrossRef citations to date
0
Altmetric
Review

Cutaneous allergies in tropical countries

, &
Pages 639-654 | Published online: 10 Jan 2014

References

  • Naafs B. Allergic skin reactions in the tropics. Clin. Dermatol.24, 158–167 (2006).
  • Gibbs S. Skin diseases and socioeconomic conditions in rural Africa: Tanzania household dermatology. Int. J. Dermatol.35, 633–639 (1996).
  • Canizares O. Epidemiology and Ecology of Skin Diseases in the Tropics and the Subtropics. Manual of Dermatology for Developing Countries. Oxford University Press, Oxford, UK, 21–34 (1982).
  • Baghestani S, Zare S, Mahboobi AA. Skin disease patterns in Hormozgan, Iran. Int. J. Dermatol.44(8), 641–645 (2005).
  • Taylor SC. Skin of color: biology, structure, function, and implications for dermatologic disease. J. Am. Acad. Dermatol.46, S41–S62 (2002).
  • Koulikova P, Hogg KG, Kolakova L, Mountford AP. Caercarial dermatitis caused by bird schistosomes comprises both immediate and late types hypersensitivity reactions. J. Immunol.172, 3766–3774 (2004).
  • Hide M, Tanaka T, Yamamura Y et al. IgE-mediated hypersensitivity against human sweat antigen in patients with atopic dermatitis. Acta Derm. Venereol.82(5), 335–340 (2002).
  • Valenta R, Seiberler S, Natter S et al. Autoallergy; a pathogenic factor in atopic dermatitis? J. Allergy Clin. Immunol.105, 432–437 (2000).
  • Innes Asher M, Bjorksten B, Lai CK et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis and eczema in childhood: ISAAC Phases one and three repeat multicountry cross-sectional surveys. Lancet368, 733–743 (2006).
  • Weiland SK, Husing A, Strachan DP et al. Climate and the prevalence of symptoms of asthma, allergic rhinitis and atopic eczema in children. Occup. Environ. Med.61, 609–615 (2004).
  • Ellwood P, Asher MI, Bjorksten B et al. Diet and asthma, allergic rhinoconjunctivitis and atopic eczema symptom prevalence: an ecological analysis of the International Study of Asthma and Allergies in childhood (ISAAC) data. Eur. Respir. J.17, 436–443 (2001).
  • Odueko OM, Onayemi O, Oyedeji GA. A prevalence survey of skin diseases in Nigerian children. Niger. J. Med.10, 64–67 (2001).
  • Alabi GO. The pattern of common childhood dermatoses in Ibadan. Niger. J. Paediatr.4, 39–42 (1980).
  • Onayemi O, Isezuo SA, Njoku CH. Prevalence of different skin conditions in an outpatients’ setting in north-western Nigeria. Int. J. Dermatol.44(1), 7–11 (2005).
  • Nnoruka EN. Skin diseases in south-east Nigeria: a current perspective. Int. J. Dermatol.44(1), 29–33 (2005).
  • Nnoruka EN. Current epidemiology of atopic dermatitis in south-eastern Nigeria. Int. J. Dermatol.43(10), 739–744 (2004).
  • Elston DM. The hygiene hypothesis and atopy: bring back the parasites? J. Am. Acad. Dermatol.54, 172–179 (2006).
  • Van Hees CLM, Naafs B. Common Skin Diseases in Africa, an Illustrated Guide. Stichting Troderma, Voorburg, The Netherlands (2001).
  • Jacyk WK. Clinical and pathologic observations in dermatitis cruris pustulosa et atrophicans. Int. J. Dermatol.17(10), 802–807 (1978).
  • Agero AL, Verallo-Rowell VN. A randomized double-blind trial comparing extra virgin coconut oil with mineral oil as a moisturizer for mild to moderate xerosis. Dermatology15, 109–116 (2004).
  • Olumide YM. Contact dermatitis in Nigeria. Contact Derm.12, 241–246 (1985).
  • Moriearty PL, Pereira C, Guimaraes NA. Contact Dermatitis in Salvador, Brazil. Contact Derm.4, 185–189 (1978).
  • Deleo VA, Taylor SC, Belsito DV et al. The effect of race and ethnicity on patch test results. J. Am. Acad. Dermatol.46, S106–S112 (2002).
  • Sharma VK, Chakrabarti A. Common contact sensitizers in Chandigarh, India. A study of 200 patients with the European standard series. Contact Derm.38, 127–131 (1998).
  • Bajaj AK, Gupta SC, Chatterjee AK, Singh KG. Shoe dermatitis in India. Contact Derm.19, 372–375 (1988).
  • Bajaj AJ, Gupta SC, Chatterjee AK, Singh KG. Shoe dermatitis in India: further observations. Contact Derm.24, 149–151 (1991).
  • Brancaccio RR, Brown LH, Chang YT, Fogelman JP, Mafong EA, Cohen DE. Identification and quantification of para-phenylenediamine in a temporary black henna tattoo. Am. J. Contact Dermat.13(1), 15–18 (2002).
  • Kang IJ, Lee MH. Quantification of para-phenylenediamine and heavy metals in henna dye. Contact Derm.55(1), 26–29 (2006).
  • Kumar AS. Pandhi RR, Bhutani LK. Bindi dermatoses. Int. J. Dermatol.25, 434–435 (1986).
  • Tewary M, Ahmed I. Bindi dermatits to ‘chandan’ bindi. Contact Derm.55, 372–374 (2006).
  • Macedo MS, de Avelar Alchorne AO, Borges Costa E, Montesano FT. Contact allergy in male construction workers in Sao Paulo, Brazil, 2000–2005. Contact Derm.56, 232–234 (2007).
  • Lim YL, Goon A. Occupational skin diseases in Singapore, 2003–2004 an epidemiologic update. Contact Derm.56, 157–159 (2007).
  • Singhal V, Reddy BS. Common sensitizers in Delhi. J. Dermatol.27, 440–445 (2000).
  • Goh CL. Occupational allergic contact dermatitis Rengas wood. Contact Derm.18, 300 (1988).
  • Epstein WL. Poison oak and poison ivy dermatitis as an occupational problem. Cutis13, 544–548 (1974).
  • Verma KK, Sirka CS, Ramam M et al. Parthenium dermatitis presenting as a lichenoïd photosensitive eruption. A new variant. Contact Derm.,46, 286–289 (2002).
  • Cole DC, Carpio F, Mat JJ et al. Dermatitis in Ecuadorian farm workers. Contact Derm.37, 1–8 (1997).
  • Goh CL. Prevalence of contact allergy by sex, race and age. Contact Derm.14, 237–240 (1986).
  • Rietschel RL. Fisher’s Contact Dermatitis (4th Edition). Lippincott Williams & Wilkins, MD, USA (1995).
  • Cole CL, Kwok SF. The influence of temperature on the concentration homogeneity of patch test materials. Contact Derm.15, 231–234 (1986).
  • Pirmohamed M, Park BK. HIV and drug allergy. Curr. Opin. Allergy Clin. Immunol.1, 311–316 (2001).
  • Temesgen Z, Beri G. HIV and drug allergy. Immunol. Allergy Clin. North Am.24, 521–531 (2004).
  • Vilar FJ, Naisbitt DJ, Park BK, Pirmohamed M. Mechanisms of drug hypersensitivity in HIV-infected patients: the role of the immune system. J. HIV Ther.8, 42–47 (2003).
  • Shibuyama S, Gevorkyan A, Yoo U et al. Understanding and avoiding antiretroviral adverse events. Curr. Pharm. Des.12, 1075–1090 (2006).
  • Cressey TR, Lallemant M. Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update. Infect. Genet. Evol.7(2), 333–342 (2007).
  • Zucman D, de Truchis P, Majerholc C et al. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed french HIV population. J. Acquir. Immune Defic. Syndr.45(1), 1–3 (2007).
  • Littera R, Carcassi C, Masala A et al. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS20(12), 1621–1626 (2006).
  • Martin AM, Nolan D, James I et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS19(1), 97–99 (2005).
  • Hunziker T, Künzi I, Braunzweig S et al. Comprehensive hospital drug monitoring: adverse skin reactions, a 20-year survey. Allergy52, 388–393 (1997).
  • Sushma M, Noel MV, Ritika MC, James J, Guido S. Cutaneous adverse drug reactions: a 9-year study from a South Indian Hospital. Pharmacoepidemiol. Drug Saf.14, 567–570 (2005).
  • Bharija SC, Belhaj MS. Fixed drug eruption due to cotrimoxazole. Australas. J. Dermatol.30(1), 43–44 (1989).
  • Puavilai S, Choonhakarn C. Drug eruptions in Bangkok: a 1-year study at Ramathibodi Hospital. Int. J. Dermatol.37(10), 747–751 (1998).
  • Puavilai S, Noppakun N, Sitakalin C et al. Drug eruptions at five institutes in Bangkok. J. Med. Assoc. Thai.88, 1642–1650 (2005).
  • Mahboob A, Haroon TS. Drugs causing fixed drug eruptons: a study of 450 cases. Int. J. Dermatol.37, 833–838 (1998).
  • Nnoruka EN, Ikeh VO, Mbah AU. Fixed drug eruption in Nigeria. Int. J. Dermatol.45, 1062–1065 (2006).
  • Kuaban C, Bercion R, Koulla-Shiro S. HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone free anti-tuberculosis treatment in Yaounde, Cameroon. East Afr. Med. J.74, 474–477 (1997).
  • Ipuge YA, Rieder HL, Enarson DA. Adverse cutaneous reactions to thiacetazone for tuberculosis treatment in Tanzania. Lancet346, 657–660 (1995).
  • Bachot N, Roujeau JC. Differential diagnosis of severe cutaneous drug eruptions. Am. J. Clin. Dermatol.4, 561–572 (2003).
  • Wöhrl S. Clinical work-up of adverse drug reactions. Expert Rev. Dermatol.2, 217–231 (2007).
  • Straatmann A, Bahia F, Pedral-Sampaio D, Brites C. A randomized, pilot trial comparing full versus escalating dose regimens for the desensitization of AIDS patients allergic to sulfonamides. Braz. J. Infect. Dis.6, 276–280 (2002).
  • Barham KL, Jorizzo JL, Grattan B, Cox NH. Vasculitis and neutrophilic vascular reactions. In: Rook’s Textbook of Dermatology (7th Edition). Burns DA, Breathnach SM, Cox NH, Griffiths CEM (Eds). Blackwell Publishing, Oxford, UK (2004).
  • Mertz A, Ozaras R, Tabak F, Pekmezci S, Demirkesen C, Ozturk R. Erythema nodosum; an experience of 10 years. Scand. J. Infect Dis.200436, 424–427
  • Cribier B, Caille A, Heid E, Grosshans E. Erythema nodosum and associated diseases: a study of 129 cases. Int. J. Dermatol.37667–672 (1989).
  • Azizlerli G, Köse AA, Sarica R et al. Prevalence of Behçet’s disease in Istanbul, Turkey. Int. J. Dermatol.42, 803–806 (2003).
  • Requena L, Sanchez Yus E. Erythema nodosum. Semin. Cutan. Med. Surg.26, 114–125 (2007).
  • Naafs B. Reactions: new knowledge. Trop. Geogr. Med.46, 80–84 (1994).
  • Naafs B, Faber WR. Leprosy. In: Imported Skin Diseases. Faber WR, Hay RJ, Naafs B (Eds). Elsevier Gezondheidszorg, Maarssen, The Netherlands, 89–103 (2006).
  • Naafs B. Treatment of reactions and nerve damage. Int. J. Lepr.64, S21–S28 (1996).
  • Schreuder PAM, Naafs B. Chronic recurrent ENL, steroid dependant: long-term treatment with high dose of clofazimine. Lepr. Rev.74, 386–389 (2003).
  • Naafs B. The skin. In: Principles of Medicine in Africa (3rd Edition). Parry E, Godfrey R, Mabey D, Hill G (Eds). Cambridge University Press, Cambridge, UK, 1264–1301 (2004).
  • Katta R. Lichen planus. Am. Fam. Physician.61, 3327–3328 (2000).
  • Daramola OO, George AO, Ogunbigi AO. Hepatitis C and lichen planus in Nigerians: any relationship? Int. J. Dermatol.41, 217–219 (2002).
  • Collen AFS, Kroon FP, Schippers EM, Naafs B, Lavrijsen APM. Drie dermatologische uitingen van immune reconstitution disease (IRD). Ned. Tijdschr. Dermatol. Venereol.15, 22–25 (2005).
  • Van Hees CLM. Persistent insect bites. In: Imported Skin Diseases. Faber WR, Hay RJ, Naafs B (Eds). Elsevier Gezondheidszorg, Maarssen, The Netherlands 259–267 (2006).
  • Demain JG. Papular urticaria and things that bite in the night. Curr. Allergy Asthma Rep.3, 291–303 (2003).
  • Steen CJ, Carbonaro PA, Schwartz RA. Arthropods in dermatology. J. Am. Acad. Dermatol.50, 819–842 (2004).
  • Penneys NS, Nayar JK, Bernstein H. Circulating antibody detection in human serum to mosquito salivary gland protein by avian biotin peroxidase. J. Am. Acad. Dermatol.18, 87–92 (1988).
  • Garcia E, Halpert E, Rodriguez A. Immune and histopathologic examination of flea bite induced papular urticaria. Ann. Allergy Asthma Immunol.92, 446–452 (2004).
  • Stibich AS, Schwartz RA. Papular urticaria. Cutis68, 89–91 (2001).
  • Naafs B. Tropical holiday memories. Eur. J. Dermatol.9, 500–506 (1999).
  • Hengge UR, Currie BJ, Jäger G, Lupi O, Schwartz RA. Scabies an ubiquitous neglected skin disease. Lancet Infect. Dis.6, 769–779 (2006).
  • Chosidow O. Scabies and pediculosis. Lancet355, 819–822 (2000).
  • Jackson A, Heukelbach J, Filho AF, Júnior Ede B, Feldmeier H. Clinical features and associated morbidity of scabies in a rural community in Alagoas, Brazil. Trop. Med. Int. Health12, 493–502 (2007).
  • Downs A. Comparing antiscabies treatments. Arch. Dermatol.133, 526 (1997).
  • Burkhart CN, Burkhart CG. Another look at ivermectin in the treatment of scabies and head lice. Int. J. Dermatol.38, 235 (1999).
  • Bryceson ADM, Hay RJ. Schistosomiasis, cercarial dermatitis. In: Textbook of Dermatology, (5th Edition). Champion RH, Burton JL, Ebling FGJ (Eds). Blackwell Scientific Publications, Oxford, UK, 1237–1240 (1992).
  • Polderman AM. Ch 17 Schistosomiasis . In: Imported Skin Diseases. Faber WR, Hay RJ, Naafs B (Eds). Elsevier Gezondheidszorg, Maarssen, The Netherlands 227–232 (2006).
  • Butterworth AE, Ouma JH, Schistosomiasis. In: Principles of Medicine in Africa (3rd Edition). Parry E, Godfrey R, Mabey D, Hill G (Eds). Cambridge University Press, Cambridge, UK 411–430 (2004).
  • Stuiver PC. Acute Schistosomiasis (Katayama Fever). Br. Med. J.288, 221–222 (1984).
  • Kager PA, Schipper HG. Acute schistosomiasis: fever and eosinophilia, with or without urticaria, after a trip to Africa. Ned. Tijdschr. Geneeskd.,145(5), 220–225 (2001).
  • Ross AG, Vickers D, Olds GR, Shah SM, McManus DP. Katayama syndrome. Lancet Infect. Dis.7, 218–224 (2007).
  • Nwokolo C. Loiaiasis In: Principles of Medicine in Africa (3rd Edition). Parry E, Godfrey R, Mabey D, Hill G (Eds). Cambridge University Press, Cambridge, UK 431–433 (2004).
  • Murdoch ME. Onchocerciasis/Filariasis. In: Imported Skin Diseases. Faber WR, Hay RJ, Naafs B (Eds). Elsevier Gezondheidszorg, Maarssen, The Netherlands, 208–225 (2006).
  • Murdoch ME, Hay RE, Mackenzie CD et al. A clinical classification and grading system of the cutaneous changes in onchocerciasis. Br. J. Dermatol.129, 260–269 (1993).
  • Hoeraf A, Mand S, Adjei O, Fleisher B, Buttner DW. Depletion of Wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectine treatment. Lancet357, 1415–1416 (2001).
  • Price EW. Non-filarial elephantiasis-confirmed as a geochemical disease, and renamed podoconiosis. Ethiop. Med. J.26, 151–153 (1988).
  • Vagas B, Ryan TJ. Lymphoedema: Pathophysiology and management in resource-poor settings. Relevance for lymphatic filariasis –control programmes. Filaria J.12, 4 (2003).
  • Hertl M. Humoral and cellular autoimmunity in autoimmune bullous skin disorders. Int. Arch. Allergy Immunol.122, 91–100 (2000).
  • Mahe A, Flagueul B, Cisse I. Pemphigus in Mali: a study of 30 cases. Br. J. Dermatol.134, 114–119 (1996).
  • Kallel Sellami M, Ben Ayed M, Mouquet H et al. Anti–desmoglein 1 antibodies in Tunisian healthy subjects: arguments for the role of environmental factors in the occurrence of Tunisian pemphigus foliaceus. Clin. Exp. Immunol.137, 195–200 (2004).
  • Abreu-Velez AM, Beutner EH, Montaya F et al. Analyses of autoantigens in a new form of endemic pemphigus foliaceus in Colombia. J. Am. Acad. Dermatol.49, 609–614 (2003).
  • Diaz LA, Sampaio SA, Rivitti EA et al. Endemic pemphigus foliaceus (Fogo Selvagem): II. Current and historic epidemiologic studies. J. Invest. Dermatol.92, 4–12 (1989).
  • Aoki V, Millikan RC, Rivitti EA. Environmental risk factors in endemic pemphigus foliaceus (fogo selvagem). J. Investig. Dermatol. Symp. Proc.9, 34–40 (2004).
  • Kanwar AJ, Sandhu K, Handa S. Chronic bullous dermatosis of childhood in North India. Pediatr. Dermatol.21, 6120–6122 (2004).
  • Oranje AP, Vuzevski VD, van Joost T. Bullous pemphigoid in children. Report of three cases with special emphasis on therapy. Int. J. Dermatol.30, 339–342 (1991).
  • Powell J, Kirtschig G, Allen J. Mixed bullous disease of childhood: a good response to antimicrobials. Br. J. Dermatol.144, 769–774 (2001).
  • Hall RP. Dermatitis herpetiformis. J. Invest. Dermatol.99, 873–881 (1992).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.